Objective: This study investigated harm reduction (HR) strategies at our institution to decrease the number of patients with a substance use disorder (SUD) who left against medical advice (AMA).
Background: HR is a public health strategy used for adult substance use problems for whom abstinence is not feasible.
Methods: An HR program was established at 1 institution to enhance the care of hospitalized patients with a SUD.
Results: Of the 1780 unique visits for patients with a diagnosis of SUD, 311 patients (17.5%) left our hospital AMA or eloped. The average length of stay for all patients evaluated by the HR team was 6.6 days compared with 4.0 days for those who left AMA. Patients with >1 hospital stay accounted for 22% of our population but represented 34% of the patients who left AMA.
Conclusions: This study reports the approaches implemented to reduce the AMA rate of patients with a SUD and to promote patient-enhanced care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/NNA.0000000000001259 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFEstimating the Cost-Saving Threshold of a Rural Syringe Services Program Before and During the COVID-19 Pandemic.
AIDS Behav
January 2025
Department of Health, Behavior and Society , Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Hampton House 184, Baltimore, MD, 21205, USA.
This study aimed to examine shifts in the cost-savings threshold of a rural syringe services program (SSP) that resulted in the 12-months following the identification of the COVID-19 pandemic. We compared SSP operational costs during the 12-months immediately before and after identification of the COVID-19 pandemic using administrative data from the Cabell-Huntington Harm Reduction Program (CHHRP), which is operated by the Cabell-Huntington Health Department in West Virginia. Data included monthly counts of client encounters, sterile syringe distribution, and HIV testing.
View Article and Find Full Text PDFDifferential Effects of Alcohol Policies Across Race/Ethnicity and Socioeconomic Status.
Alcohol Res
January 2025
Prevention Research Center, Pacific Institute for Research and Evaluation, Berkeley, California.
Purpose: Sociocultural characteristics, including race/ethnicity and socioeconomic status (SES), may affect individuals' attitudes and norms regarding alcohol use and treatment as well as their access to emerging health knowledge, innovative technologies, and general resources for improving health. As a result of these differences, as well as social determinants of health such as stigma and uneven enforcement, alcohol policies may not benefit all population subgroups equally. This review addresses research conducted within the last decade that examined differential effects of alcohol policies on alcohol consumption, alcohol harm, and alcohol treatment admissions across racial/ethnic and socioeconomic groups.
View Article and Find Full Text PDF"Smoking weed it gets you over the hump": Cannabis co-use as a facilitator of decreased opioid use among people who inject drugs in Los Angeles, California.
Drug Alcohol Depend Rep
September 2024
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Introduction: Opioid overdose mortality rates have surged dramatically in the last decade due largely to fentanyl in the illicit US drug supply. As of June 2024, 38 states, three territories, namely US Virgin Islands, Guam and the Northern Mariana Islands, and the District of Columbia, allow the medical use of cannabis products. However, there remains limited qualitative community-based evidence on the role of cannabis co-use among opioid using and injecting populations.
View Article and Find Full Text PDF'Zombie drugs': Dehumanising news frames and public stigma towards people who use drugs.
Int J Drug Policy
January 2025
School of Psychological Sciences, University of Bristol, Bristol, UK.
Background: News media is an important determinant of public understanding of drug policy topics. Recent media reporting around the use of synthetic drugs such as xylazine makes frequent use of non-human metaphors, including reference to the effects of 'zombie drugs'. We investigated whether presentation of news stories which included such dehumanising frames were associated with i) increased stigmatising attitudes towards people who use drugs; and ii) lower support for relevant harm reduction programmes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!